NCM · Medical - Devices

LENSAR, Inc. (LNSR) Stock

$6.07 +0.83% NCM: LNSR Healthcare

Valuation

MetricValue
Price$6.07
Market Cap$74.58M
P/E Ratio5.25
P/B Ratio5.50
P/S Ratio1.36
EPS (TTM)$-2.87
52-Week High$12.94
52-Week Low$4.95
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-514.92%
ROA49.88%
ROCE-16.28%
Gross Margin-43.10%
Operating Margin-43.10%
Net Margin57.57%
Debt/Equity0.16
Current Ratio1.15

Annual Financials (USD)

Metric20212022202320242025
Revenue$34.0M$35.0M$42.0M$53.0M$58.0M
Operating Profit$-20.0M$-20.0M$-12.0M$-11.0M$-25.0M
Net Profit$-20.0M$-20.0M$-14.0M$-31.0M$-34.0M
EPS$-2.10$-1.96$-1.31$-2.73$-2.87
Op Margin-57.0%-57.1%-29.0%-19.9%-42.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$66.0M$56.0M$70.0M$66.0M$71.0M
Total Liabilities$12.0M$14.0M$22.0M$48.0M$97.0M
Cash$32.0M$15.0M$21.0M$16.0M$13.0M
Borrowings$3.0M$3.0M$2.0M$3.0M$3.0M

Latest News

Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now? Zacks · Jul 2, 2026 How The LENSAR (LNSR) Story Is Shifting After The Failed Deal And New $10 Target Simply Wall St. · Jun 4, 2026 Lensar (LNSR) Q1 2026 Earnings Transcript Motley Fool · Jun 1, 2026 Lensar (LNSR) Q4 2025 Earnings Transcript Motley Fool · Jun 1, 2026 LENSAR Q1 Earnings Call Highlights MarketBeat · May 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-9.0M$-15.0M$-10.0M$-2.0M$-15.0M
Investing Cash Flow$-1.0M$0$-4.0M$-2.0M$1.0M
Financing Cash Flow$0$-2.0M$0$0$10.0M
Net Cash Flow$-9.0M$-17.0M$6.0M$-4.0M$-3.0M
Free Cash Flow$-9.0M$-15.0M$-10.0M$-2.0M$-15.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.02
EV / EBITDA1.99
FCF Yield-8.95%
Quick Ratio1.13
Interest Coverage—
Return 1Y-55.00%
Return 3Y59.05%
Return 5Y-22.59%

Ownership

Insiders Held21.53%
Institutions Held52.01%
Institutions Float Held66.28%
Institutional HolderSharesReport Date
Brandes Investment Partners L.P.1,025,1762026-03-31
Blackrock Inc.628,7482026-03-31
Vanguard Capital Management LLC390,0902026-03-31
Geode Capital Management, LLC229,7402026-03-31
Dimensional Fund Advisors LP224,9342026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANIKAnika Therapeutics Inc. $21.42 +1.56% -70.87 $286.66M 0.00%
ARAYAccuray Incorporated $0.13 -2.91% -0.71 $15.54M 0.00%
AVRAnteris Technologies Global Corp. $5.87 -2.17% -2.74 $572.08M 0.00%
CRBPCorbus Pharmaceuticals Holdings, Inc. $4.05 -1.94% -0.95 $78.33M 0.00%
CRDFCardiff Oncology, Inc. $0.91 -2.23% -1.87 $70.58M 0.00%

About LENSAR, Inc.

LENSAR, Inc. is led by CEO Nicholas T. Curtis, employs 140 people, headquartered in US, publicly traded since 2020.

LENSAR, Inc. (LNSR) stock trades at $6.07 with a market capitalization of $74.58M. The stock is valued at a price-to-earnings (P/E) ratio of 5.25, price-to-book of 5.50, price-to-sales of 1.36. Over the past 52 weeks the stock has ranged between $4.95 and $12.94, and currently trades 53.1% below its 52-week high.

On profitability, LENSAR, Inc. generates a return on equity (ROE) of -514.92% (negative, reflecting a net loss), return on capital employed of -16.28%, an operating margin of -43.10%, a net profit margin of 57.57%.

LENSAR, Inc. by the numbers, 2018–2025

Between 2018 and 2025 LENSAR, Inc. reported revenue of $24.0M rising to $58.0M, a change of +141.7% across 8 years. Compounded, revenue has grown 17.4% a year over five years, 18.3% over three, 9.4% over the last twelve months. Net profit fell to $-34.0M.

Operating margin went from -38.2% in 2018 to -42.1% in 2025, a fall of 3.9 percentage points. The most recent net margin is 57.57%. On a trailing twelve-month basis to Jun '26, revenue is $59.0M and net profit $35.0M.

Borrowings fell from $41.0M to $3.0M, cash from operations was $-15.0M in the latest year, positive in 0 of the last 8.

Return on equity has averaged -29.2% over five years, and was 130.8% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

LENSAR, Inc. (LNSR) — frequently asked questions

What is LENSAR, Inc. (LNSR) stock price today?

LENSAR, Inc. (LNSR) is currently trading at $6.07, up 0.83% today.

What is LNSR P/E ratio?

LENSAR, Inc.'s P/E ratio is 5.25. This is below the typical market average of roughly 18-22x. A low P/E can reflect a lower valuation, slower expected growth, or both.

What is LNSR return on equity (ROE)?

LENSAR, Inc.'s return on equity (ROE) is -514.92%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is LENSAR, Inc.'s market cap?

LENSAR, Inc. has a market capitalization of $74.58M.

Does LNSR pay a dividend?

LENSAR, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does LNSR carry?

LENSAR, Inc. has a debt-to-equity ratio of 0.16. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is LNSR's profit margin?

LENSAR, Inc. reports a net profit margin of 57.57% — the share of revenue left after every cost, including tax and interest.

What sector is LNSR in?

LENSAR, Inc. is classified under Healthcare, in the Medical - Devices industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is LNSR listed on?

LENSAR, Inc. trades on NCM under the ticker LNSR.

What is LNSR's 52-week range?

Over the last year LENSAR, Inc. has traded between $4.95 and $12.94.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens LNSR currently matches

On the figures above, LENSAR, Inc. passes the filters for 1 of our ready-made screens, among them Micro Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Micro Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.